About Therastel Labs
Building a platform company around therapeutic bioelectric modulation.
TheraStel Labs is a biotech company developing localized, sustained-release therapeutics designed to modulate cellular bioelectric states in cancer.
​
Our approach is built around — Smart Injectable Hydrogel Delivery — SIHD, a proprietary delivery system intended to position active compounds directly within target tissue while reducing unnecessary systemic exposure.
Platform
SIHD- enabled localized delivery
Lead Asset
SIHD - CZX
Focus
Chemo-Resistant Breast Cancer
Our Strategy
Pipeline of Ion-Channel–Targeted Therapeutics
The company is building a pipeline of ion-channel–targeted oncology therapeutics enabled by its Smart Injectable Hydrogel Delivery platform (SIHD). This integrated strategy combines a novel therapeutic mechanism with localized drug delivery technology designed to achieve sustained intra-tumoral exposure to therapeutic agents while minimizing systemic toxicity.
Bioelectric Research
Researching and developing bioelectric-based technologies with the potential to transform cancer treatment and improve patient outcomes.
Innovative Solutions
Developing innovative therapeutic solutions by engaging the tumor at a local level to address unmet medical needs and improve patient outcomes in cancer treatment.
Tailored Precision Medicine
Advancing precision medicine for the customization of treatments to individual patients based on their diagnosis, standard of care and specific health needs, ensuring more effective and precise care.
